Storia in 2 fonti

Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon

The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.com4 g fa

Symbiotec Pharmalab gets Rs 526 crore anchor backing ahead of IPO; Citi Group, Singularity among investors

Symbiotec Pharmalab secured Rs 526.20 crore anchor backing (Citi, HDFC, Singularity) for IPO opening August 24, targeting Rs 1,757 crore total. The pharmaceutical APIs manufacturer with FDA/EU-GMP approvals reflects institutional confidence in India's regulated biotech sector.

Leggi questa versione → originale

thehindubusinessline.com4 g fa

Symbiotec Pharmalab raises Rs 526 crore from anchor investors ahead of IPO

Symbiotec Pharmalab raises Rs 526 crore from anchors at Rs 988/share for its Rs 1,757-crore IPO opening August 24. Strong upper-band pricing signals investor confidence in India's specialized-API biotech sector amid broader IPO activity.

Timeline cronologica

venerdì 21 agosto 2026·economictimes.indiatimes.com
Symbiotec Pharmalab gets Rs 526 crore anchor backing ahead of IPO; Citi Group, Singularity among investors
Symbiotec Pharmalab has raised Rs 526.20 crore from anchor investors ahead of its Rs 1,757 crore IPO opening August 24. The pharmaceutical company has set a Rs 938-988 price band,…
venerdì 21 agosto 2026·thehindubusinessline.com
Symbiotec Pharmalab raises Rs 526 crore from anchor investors ahead of IPO

Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon

Confronto fonti

Symbiotec Pharmalab gets Rs 526 crore anchor backing ahead of IPO; Citi Group, Singularity among investors

Symbiotec Pharmalab raises Rs 526 crore from anchor investors ahead of IPO

Timeline cronologica

Symbiotec Pharmalab gets Rs 526 crore anchor backing ahead of IPO; Citi Group, Singularity among investors

Symbiotec Pharmalab raises Rs 526 crore from anchor investors ahead of IPO

Symbiotec Pharmalab IPO analysis: Key factors investors need to know before subscribing

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Symbiotec Pharmalab IPO opens today: Price, dates and key details

Symbiotec Pharmalab IPO opens today: GMP signals 41% upside — Should you subscribe?

Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon

Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?